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Secondary cannabis use among London drug treatment service clients 
Background Cannabis is the second most commonly used substance after alcohol among 
people seeking treatment for other drug use, but no statistics are available regarding 
secondary cannabis use among drug treatment clients. 
Objectives To investigate levels of secondary cannabis use among drug treatment clients and 
perceived need for support addressing this use among clients and staff. 
Methods Cross-sectional surveys of clients (N=295) and staff (N=33) were conducted in 
2015 at four London drug and alcohol treatment services. Client measures included recent 
drug use, type of cannabis used, Severity of Dependence Scale for cannabis, and views on 
secondary cannabis use treatment. Staff measures included definition of problem cannabis 
use, importance and timing for addressing secondary cannabis use. 
Results Amongst clients, 39.7% reported recent secondary cannabis use, with 30.8% of these 
clients meeting criteria for problem use. Problem users were more likely to be interested in 
receiving treatment for cannabis use than non-problem users (51.4% vs 10.8%, p<0.001). 
Nearly half of staff (48.5%) thought secondary cannabis use should be addressed early in 
treatment. 
Conclusions Two out of five drug treatment clients used cannabis and a third experienced 
cannabis-related problems. Many are willing to address cannabis use, but defined treatment 
pathways are needed. 
 
Key words cannabis; cannabis use disorder; substance use disorder, treatment 
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Introduction 
 Cannabis is the most commonly used illicit drug worldwide (United Nations Office on Drugs 
and Crime, 2014). In Europe, the number of individuals seeking specialised drug treatment services 
for cannabis use problems has doubled between 2003 and 2014 (Montanari, Guarita, Mounteney, 
Zipfel, & Simon, 2017). Between 2005 and 2015, past-year cannabis use in the general population of 
England and Wales has decreased from 8.7% to 6.7% (Home Office, 2015). However, for the same 
period the number of new clients entering drug treatment for primary cannabis use problems has 
increased by 21%, mostly among 18-24 year-olds (Public Health England, 2016). No official statistics 
are available regarding secondary cannabis use among UK drug treatment service clients, and clinical 
guidelines do not explicitly address this issue in the formulation of treatment plans (Department of 
Health (England) and the devolved administrations, 2007; Independent Expert Working Group, 2017). 
Hence it remains unknown if cannabis use causes additional treatment needs in those receiving 
treatment for other drug dependence. 
 In Europe, cannabis is the second most commonly misused substance after alcohol among 
clients seeking treatment for dependency on other drugs (Montanari, Taylor, & Griffiths, 2008). A 
systematic review of 22 studies estimated that on average 32.9% of methadone maintenance treatment 
clients had recently used cannabis (Zielinski et al., 2016), and other studies report that between 29% 
and 79% of people in treatment for opioid and cocaine dependence also used cannabis while in 
treatment (Aharonovich et al., 2005; Best et al., 1999; Budney, Bickel, & Amass, 1998; Epstein & 
Preston, 2003; Mojarrad, Samet, Cheng, Winter, & Saitz, 2014; Nirenberg, Cellucci, Liepman, Swift, 
& Sirota, 1996; Saxon et al., 1993; Wasserman, Weinstein, Havassy, & Hall, 1998; Weizman, 
Gelkopf, Melamed, Adelson, & Bleich, 2004; Zielinski et al., 2017). UK data on secondary cannabis 
use among drug treatment services clients is limited, but a 1999 study of 200 methadone maintenance 
treatment clients found that 60% had used cannabis in the last month and 40% were daily users (Best 
et al., 1999). Although cannabis has been discussed as a substitute for alcohol or opioids (Reiman, 
2009; Subbaraman, 2014), whether cannabis use is a help or a hindrance in the context of addiction 
treatment is still a subject of debate. Findings in this area are inconsistent: some studies concluded 
Secondary cannabis use among drug treatment clients 
4 
 
that cannabis use might predict a relapse following substance misuse treatment (Aharonovich et al., 
2005; Mojarrad et al., 2014; Wasserman et al., 1998), but the majority of research to date has not 
found that secondary cannabis use has an adverse impact on other drug treatment outcomes (Best et 
al., 1999; Budney et al., 1998; Epstein & Preston, 2003; Nirenberg et al., 1996; Saxon et al., 1993; 
Weizman et al., 2004). However, research in this field has sparsely investigated if cannabis use or 
withdrawal cause harm or create additional treatment needs (Budney et al., 1998; Chauchard, 
Goncharov, Krupitsky, & Gorelick, 2014; Dennis, Babor, Roebuck, & Donaldson, 2002; Hesse & 
Thylstrup, 2013). 
 Given the small and inconclusive evidence base, the lack of consensus regarding the need to 
address secondary cannabis use during addiction treatment is not surprising. Very few services focus 
exclusively on the treatment of cannabis use (National Collaborating Centre for Mental Health, 2008), 
and while drug treatment guidance advises cannabis use should be monitored throughout a treatment 
episode, no clear instruction is provided for how to identify or support problem secondary cannabis 
users (Department of Health (England) and the devolved administrations, 2007; Independent Expert 
Working Group, 2017). Patient-initiated treatment is also rare: only 7% of those with 12-month 
cannabis use disorder and 14% with lifetime cannabis use disorder seek treatment. (Hasin et al., 
2016). Cannabis misusers mostly look for support prompted by dependence symptoms, induced or 
aggravated mental health problems, or past treatment experience (Agosti & Levin, 2004; van der Pol 
et al., 2013). Among secondary cannabis users treatment-seeking may be even lower as primary drug 
use harms might obscure negative cannabis use effects (Budney et al., 1998; Chauchard et al., 2014; 
Hesse & Thylstrup, 2013). 
 Therefore, we aimed to investigate (i) the level of secondary cannabis use among drug 
treatment service clients; (ii) perceived need for, and availability of, support for secondary cannabis 
use from client and staff perspectives. 
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Methods 
Study design and participant recruitment 
 Multi-site cross-sectional anonymous questionnaire surveys of clients and staff were 
administered in four South London and Maudsley NHS Trust (SLaM) community drug and alcohol 
treatment services between July and August 2015. The questionnaires were completed by participants, 
with a member of the research team available to read questions aloud and provide clarification for 
clients with literacy difficulties. Client participants were recruited via convenience sampling, with all 
clients approached and given a verbal explanation of the study purpose and content, assured of 
confidentiality and anonymity, and that their responses will not affect their current treatment. The 
questionnaire was provided to those who gave verbal consent. Staff participants were recruited by a 
member of the research team presenting an overview of the study during a staff meeting and 
distributing the surveys to staff in attendance. Staff could return the questionnaire to the research team 
member at that time, or at another time of their choosing. No members of the research team had 
existing professional or personal relationships with potential participants. In total, 295 drug treatment 
service clients (response rate 85.8%) and 33 staff members participated in the survey. The study was 
approved by the local SLaM NHS Foundation Trust Audit Committee in May 2015. 
Measures 
Client questionnaire 
 Sociodemographics: Gender was collected as a binary variable indicating male or female. 
Age was collected as continuous and then divided into four categories: 20-29, 30-39, 40-49, 50+ 
years. 
 Treatment substances: Clients were asked to indicate the substances they were currently 
receiving treatment for, with options including alcohol, tobacco, cannabis, crack, opiates/opioids, 
amphetamines, benzodiazepines, cocaine, novel psychoactive substances, cannabinoids/synthetic 
cannabinoids, and other substances with an option to specify. This was converted into a series of 
binary variables, and participants could report receiving treatment for more than one substance. 
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Where patients reported receiving treatment for two or more substances, they were categorised as 
being enrolled in polysubstance treatment. 
Drug use frequency: For the same list of drugs described above, frequency of use in the last 30 days 
(continuous) was collected. 
Cannabis use: Clients who reported using cannabis at least once in the past 30 days were 
characterised as cannabis users. Those who reported using cannabis every day in the past 30 days 
were characterised as daily cannabis users. Clients who reported currently receiving treatment 
exclusively for cannabis use problem were treated as primary cannabis users and were excluded from 
analyses pertaining to secondary cannabis use. 
 Cannabis type: All cannabis users were asked about preferred cannabis type (‘skunk, high 
potency herbal cannabis’, ‘hash, resin, solids’, or ‘normal weed, grass, bush’)(Tom P Freeman et al., 
2014). 
 Problem cannabis use: Problem users were identified by Severity of Dependence scale (SDS) 
adapted for cannabis use (Gossop et al., 2006; Martin, Copeland, Gates, & Gilmour, 2006). SDS for 
cannabis use has been shown to have a good test-retest reliability of 0.88 and a validity of 0.76 when 
comparing to number of DSM-IV cannabis dependence symptoms (Martin et al., 2006). SDS 
questions refer to last three months’ cannabis use and have response options ‘never or almost never’ 
(scored 0), ‘sometimes’ (1), ‘often’ (2), and ‘always or nearly always’ (3): 
(1) ‘Did you think your use of cannabis was out of control?’ 
(2) ‘Did the prospect of missing cannabis or not chasing make you anxious or worried?’ 
(3) ‘Did you worry about your use of cannabis?’ 
(4) ‘Did you wish you could stop?’ 
(5) ‘How difficult did you find it to stop or go without cannabis?’ 
 The sum of scores provides a measure of cannabis dependence severity; clients who scored 3 
or more were identified as problem cannabis users (Swift, Copeland, & Hall, 1998). 
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Interest in changing cannabis use: Clients were asked whether they were interested in altering their 
current cannabis use, with response options including ‘reduce’, ‘stop’, ‘no’, and ‘don’t know’. 
Interest in receiving support for changing cannabis use: Interest in receiving support was assessed 
by asking participants if they would be interested in receiving treatment or getting advice for their 
cannabis use. Response options were ‘yes’ or ‘no’. 
Offered support for cannabis use: Participants were asked if they have ever been offered support by 
a clinician to stop their cannabis use. Response options were ‘yes’ or ‘no’. 
Staff questionnaire 
 Sociodemographics: Gender was collected as binary variable indicating male or female. Age 
was collected as continuous and then divided into four categories: 20-29, 30-39, 40-49, 50+ years. 
 Professional status: Staff role was collected in line with the categories that had been used in 
similar survey (Cookson et al., 2014), but due to the small sample this was collapsed to: registered 
nurse; drug worker; manager; administrative and support staff; training grade doctor; other. 
 Professional area(s) of interest: Staff were asked to indicate their professional areas of 
interest, which were listed as ‘alcohol’; ‘tobacco’; ‘drugs’ (not mutually exclusive). 
 Definition of problem cannabis use: Staff were asked what frequency of client cannabis use 
they would consider problematic. Options were: daily; 2-3 times per week; weekly; monthly; less than 
monthly. 
 Importance of addressing secondary cannabis use: To assess the magnitude of the importance 
of addressing secondary cannabis use, staff were asked to report how important they viewed 
addressing cannabis use where it is not a clients’ primary drug using a ten-point scale (with 10 
equivalent to highest level of importance). 
 When in treatment secondary cannabis use should be addressed: Most appropriate timing for 
addressing secondary cannabis use was investigated by asking staff when they thought cannabis use 
should be addressed in treatment. Response options were: ‘Early in a client’s primary addiction 
treatment’; ‘Late in a client’s primary addiction treatment’; ‘After primary addiction treatment is 
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completed’; ‘Cannabis use does not need to be addressed during treatment for other drugs’; ‘Other 
(please specify)’. 
Analysis 
 Standard descriptive statistics were used to report characteristics of client and staff 
participants. Proportions, means, standard deviations, and 95% confidence intervals were used to 
describe clients’ cannabis use patterns, attitudes to cannabis treatment, and received support. Chi 
squared and Student t-tests for two independent samples were used to examine differences between 
problem and non-problem cannabis users regarding cannabis use characteristics, desire to change their 
use, and support received. Chi squared test was used to investigate the association between clients’ 
interest in receiving support for changing their secondary cannabis use and whether they had ever 
been offered support by clinical staff. Staff attitudes towards treatment for secondary cannabis use 
were described using means and proportions. 
Results 
Clients 
 The client sample consisted of 295 participants, the majority of whom were male (65.8%) and 
aged 40-49 years (M (SD) = 43.0 (9.6), range: 21–69; see Table 1). Almost three-quarters of clients 
were receiving treatment for opioid dependence (70.2%). Only 9.5% (N=28) reported cannabis as a 
primary treatment drug, four of them (1.4%) were in treatment exclusively for cannabis use problems, 
while 39.7% (N=117) reported secondary cannabis use. 
[Table 1 about here] 
 Amongst clients reporting secondary cannabis use, the average number of days using 
cannabis was 13.4 per month, with a quarter reporting daily use (25.6%; see Table 2). The majority of 
secondary cannabis users preferred skunk (58.1%), almost a third were identified as problem users by 
SDS score (30.8%; 12.2% of all sample). Thirty percent (29.9%) of secondary cannabis users 
expressed interest in stopping or reducing their cannabis use, but only a fifth (19.7%) had ever been 
offered support for cannabis use. Of those interested in support for secondary cannabis use, 26.9% 
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had been offered support by clinical staff compared to 18.3% of those who were not interested (2 (1) 
= 0.9, p = .34). 
[Table 2 about here] 
 Compared with non-problem secondary cannabis users, problem users had used cannabis on 
average six days more per month, were more likely to use skunk (72.2% compared to 51.9%), were 
more likely to be interested in reducing/stopping their cannabis use (48.6% compared to 24.7%), and 
to be interested in receiving support for cannabis use (51.4% compared to 10.8%). 
[Table 3 about here] 
Staff 
 The staff sample consisted of 33 participants, the majority of whom were female (54.5%), 
mostly between 50 and 59 years old (36.4%), working as registered nurses (27.9%) or drug workers 
(18.2%), and reporting professional interest in drugs (78.8%) and alcohol (78.8%; see Table 4). Most 
staff members defined problem cannabis use as daily use (60.6%), but views on the importance of 
addressing secondary cannabis use were equivocal; the mean for the ten-point scale indicating 
importance was 5.68 (SD=2.4, 95% CI: 4.8 - 6.6). Almost half of the staff participants (48.5%) 
thought the best time to address cannabis use was early in treatment, while four participants (12.1%) 
reported that cannabis use should be addressed after primary addiction treatment is completed or that 
it does not need to be addressed during treatment for other drugs. 
[Table 4 about here] 
Discussion 
 In the sample of London drug and alcohol treatment service clients, 40% reported using 
cannabis as a secondary drug in the past 30 days, with nearly a third identified as problem users based 
on SDS scores. Although more than half of problem users were interested in receiving professional 
support for secondary cannabis use, only a quarter reported that they had ever been offered support. 
The majority of staff viewed daily (as opposed to less frequent) cannabis use as problematic, with 
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about half indicating that it should be addressed early during the course of treatment for other drug 
use problems. 
 Three-quarters of problem cannabis users did not recall being offered support to reduce or 
quit using cannabis by treatment staff. As the data were self-reported, it is possible that participants 
may have been offered support but did not recall this. Nevertheless, so few problem cannabis users 
reporting that they had been offered support suggests an unaddressed treatment need. Although nearly 
half of the staff participants felt that cannabis use should be addressed early in treatment, this view 
was not universal and suggests the need for more definite treatment guidance regarding secondary 
cannabis use. There is no definitive evidence that any specific treatment could be confidently 
suggested for problem cannabis use (Schettino, Leuschner, Tossmann, & Hoch, 2015). Instead, in 
UK, a range of psychosocial interventions of uncertain efficacy are indicated for primary cannabis use 
problems (Department of Health (England) and the devolved administrations, 2007; National 
Collaborating Centre for Mental Health, 2008), while secondary cannabis use is not prioritised in 
treatment planning (Department of Health (England) and the devolved administrations, 2007; 
Independent Expert Working Group, 2017). Consequently, the lack of clear guidance creates 
discrepancies in how cannabis use is viewed by both clients and staff (Monaghan, Hamilton, Lloyd, & 
Paton, 2016). 
 More than half of the identified problem cannabis users were interested in receiving advice or 
treatment, when in general population samples one out of seven lifetime problem users seek 
professional support (Hasin et al., 2016). One explanation for this difference is that common barriers 
for seeking cannabis treatment, including a need for self-reliance and preference for informal help 
(van der Pol et al., 2013), have already been removed to some extent in those who are in drug 
treatment. Cannabis use has been shown to increase in clients who try to abstain from other drugs 
(Independent Expert Working Group, 2017); while treatment reduces harms associated with the 
misuse of a primary drug, it paradoxically could expose problems associated with persisting cannabis 
use. Daily use (Di Forti et al., 2014) and preference for high potency skunk (T. P. Freeman & 
Winstock, 2015) were confirmed as factors associated with negative secondary cannabis use 
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outcomes. The substantial proportion of clients in this study seeking support to address their cannabis 
use further underscores a need to reconsider the harm potential of secondary cannabis use. 
 A few limitations should be taken into account when interpreting study findings. Firstly, 
findings on secondary cannabis use were mainly presented from a harm perspective while positive 
effects of recreational or medical cannabis use were not covered (Duff, 2016) and could be examined 
in future research. Also, results of this convenience sample, cross-sectional study refer to associations 
rather than causal relations between variables. All data were self-reported, which could have affected 
validity: for instance, service users’ responses about past 30 days drug use or SDS scores. SDS also 
covers same dimensions as other questionnaire items do (i.e. ‘interest in changing cannabis use’), 
which could have introduced conceptual overlap issue into final results. Nonetheless, the results do 
indicate that a substantial minority of secondary cannabis users express a desire to reduce their 
cannabis use alongside other cannabis related problems. Many staff members did not return their 
questionnaires, resulting in small sample size, thus staff responses should be interpreted with care. 
However, we achieved a high response rate for clients and the estimated proportion of all cannabis 
users in this sample is similar to the most recent data reported from UK drug treatment services in 
1999 (Best et al., 1999). 
 This is only the third study in the last 20 years to evaluate the proportion and patterns of 
secondary cannabis use among UK drug treatment service clients (Best et al., 1999; McBride, 1995) 
and the first to highlight the disparity between client interest in treatment and accessing treatment. 
Improvements in clinical guidance and practice are necessary when identifying and offering support 
for secondary cannabis use, which, according to these findings, is common and elicits additional 
treatment needs in drug and alcohol treatment service clients. 
Conclusion 
 Two out of five drug treatment service clients are using cannabis and a third experience 
cannabis dependence symptoms. Problem secondary cannabis use can be successfully identified and 
many problem users are willing to address cannabis misuse with specialists’ support. However, 
current drug treatment guidelines, discordant practitioners’ views, and resources do not effectively 
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address the need for treatment of problem secondary use of cannabis alongside treatment for other 
substance misuse. 
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Tables 
Table 1 Characteristics of clients who had or had not used cannabis in the past 30 days; N = 295. 
Client characteristic Total, % (n) 
Cannabis non-users, % 
(n) 
Cannabis users, % (n) 
Total  59.0 (174) 41.0 (121) 
Gender    
 Male 65.8 (194) 67.2 (117) 63.7 (77) 
 Female 29.2 (86) 27 (47) 32.2 (39) 
 Missing 5.0 (15) 5.8 (10) 4.1 (5) 
Age group    
 20 - 29 9.2 (27) 6.9 (12) 12.4 (15) 
 30 - 39 21.7 (64) 22.4 (39) 20.7 (25) 
 40 - 49 37.6 (111) 37.9 (66) 37.2 (45) 
 50 - 59 18.0 (53) 18.4 (32) 17.3 (21) 
 60+ 4.4 (13) 3.5 (6) 5.8 (7) 
 Missing 9.1 (27) 10.9 (19) 6.6 (8) 
Primary substance(s)a    
 Opioids 70.2 (207) 67.8 (118) 73.6 (89) 
 Alcohol 25.1 (74) 27.6 (48) 21.5 (26) 
 Crack 22.7 (67) 20.7 (36) 25.6 (31) 
 Cannabis 9.5 (28) 3.5 (6) 18.2 (22) 
 Tobacco 4.1 (12) 3.5 (6) 5.0 (6) 
 Cocaine 4.1 (12) 4.0 (7) 4.1 (5) 
 Benzodiazepines 3.1 (9) 1.7 (3) 5.0 (6) 
Secondary cannabis use among drug treatment clients 
18 
 
 Other 2.0 (6) 2.3 (4) 1.7 (2) 
 Amphetamine 1.7 (5) 2.9 (5) 0 
 Synthetic 
cannabinoids 
1.4 (4) 0.6 (1) 2.5 (3) 
 Polysubstanceb 30.5 (90) 27.2 (47) 35.5 (43) 
Note: statistically significant differences between subsamples are bolded. 
a Multiple responses possible. 
b ≥ 2 substances were mentioned as primary. 
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Table 2 Patterns of secondary cannabis use and the need for support in addressing secondary cannabis use; 
N=117. 
Characteristic % (n) a 
M (SD) Average days cannabis used last month 13.4 (11.6) 
Daily cannabis users 25.6 (30) 
Type of cannabis  
 Normal 18.8 (22) 
 Skunk 58.1 (68) 
 Hash 21.4 (25) 
 Missing 1.7 (2) 
SDS ≥ 3 30.8 (36) 
Interest in changing cannabis use  
 Reducing 12.8 (15) 
 Stopping 17.1 (20) 
 Doesn’t know 6.0 (7) 
 Not interested 56.4 (66) 
 Missing 7.7 (9) 
Interest in receiving supporta for cannabis use  
 Yes 22.2 (26) 
 No 70.9 (83) 
 Missing 6.8 (8) 
Ever offered support to stop cannabis use  
 Yes 19.7 (23) 
 No 74.4 (87) 
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 Missing 6.0 (7) 
a Except where specified 
b Treatment/ advice for secondary cannabis use. 
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Table 3 Patterns of cannabis use and interest in support between problem and non-problem secondary cannabis 
users; N=117. 
Characteristic 
Problem users 
(SDS ≥ 3), % (n) a 
Non-problem users 
(SDS < 3), % (n) a 
Test statistics 
Total b 30.8 (36) 69.2 (81)  
M (SD) Average days cannabis 
used last month 
n=35 
17.5 (12.0) 
n=79 
11.5 (11.1) 
t (112) = -2.6, 
p = .005 
Using skunk 72.2 (26) 51.9 (42) 2 (1) = 4.2, p = .039 
Daily users 38.9 (16) 19.8 (16) 2 (1) = 4.8, p = .029 
Interested in reducing or 
stopping cannabis use 
n=35 
48.6 (17) 
n=73 
24.7 (18) 
2 (1) = 6.2, p = .013 
Interested in receiving support 
for cannabis use c 
n=35 
51.4 (18) 
n=74 
10.8 (8) 
2 (1) = 21.6, p < .001 
Ever were offered support to 
quit/ reduce 
n=35 
25.7 (9) 
n=75 
18.7 (14) 
2 (1) = 0.7, p = .40 
Note: statistically significant differences between subsamples are bolded. 
a Except where specified. 
b Where numbers vary due to missing data, subsamples’ sizes are indicated separately. 
c Treatment/advice for secondary cannabis use. 
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Table 4 Staff demographic and professional characteristics; N=33. 
Staff characteristics % (n) 
Gender  
 Male 39.4 (13) 
 Female 54.5 (18) 
 Missing 6.1 (2) 
Age group  
 20-29 9.1 (3) 
 30-39 21.2 (7) 
 40-49 12.1 (4) 
 50-59 36.4 (12) 
 Missing 21.2 (7) 
Profession group  
 Registered nurse 27.3 (9) 
 Drug worker 18.2 (6) 
 Manager 12.1 (4) 
 Administrative & support staff 9.1 (3) 
 Training grade doctor 6.1 (2) 
 Other 24.2 (8) 
 Missing 3.0 (1) 
Area of interesta  
 Alcohol 78.8 (26) 
 Drugs 78.8 (26) 
 Tobacco 12.1 (4) 
a Multiple responses possible. 
 
